Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
76.83
+0.77 (1.01%)
Aug 10, 2026, 10:36 AM EDT - Market open
KNSA Revenue
Kiniksa Pharmaceuticals International, had revenue of $243.60M in the quarter ending June 30, 2026, with 55.36% growth. This brings the company's revenue in the last twelve months to $840.85M, up 58.85% year-over-year. In the year 2025, Kiniksa Pharmaceuticals International, had annual revenue of $677.56M with 60.09% growth.
Revenue (ttm)
$840.85M
Revenue Growth
+58.85%
P/S Ratio
7.06
Revenue / Employee
$2,297,399
Employees
366
Market Cap
5.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 677.56M | 254.33M | 60.09% |
| Dec 31, 2024 | 423.24M | 152.98M | 56.60% |
| Dec 31, 2023 | 270.26M | 50.08M | 22.74% |
| Dec 31, 2022 | 220.18M | 181.64M | 471.24% |
| Dec 31, 2021 | 38.54M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.67B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.33B |
| Prestige Consumer Healthcare | 1.10B |
KNSA News
- 2 days ago - Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 11 days ago - Kiniksa price target raised to $90 from $75 at Goldman Sachs - TheFly
- 12 days ago - Kiniksa price target raised to $99 from $72 at Wedbush - TheFly
- 12 days ago - Kiniksa price target raised to $107 from $72 at JPMorgan - TheFly
- 12 days ago - Kiniksa price target raised to $98 from $64 at Canaccord - TheFly
- 12 days ago - Kiniksa price target raised to $100 from $60 at Citi - TheFly
- 12 days ago - Kiniksa rises 23.9% - TheFly
- 13 days ago - Kiniksa rises 22.7% - TheFly